The Venture Codex

Participated · Series B · Aug 2026

Arintra pairs large language models with clinical knowledge graphs to interpret unstructured medical charts and autonomously apply CPT, ICD-10, HCC, and HCPCS billing codes. Its platform integrates bidirectionally with major EHRs including Epic and Athenahealth to create direct-to-billing claims without manual retyping and includes audit trails linking codes to source text. In live health system rollouts the company reports documented outcomes including a 5%+ increase in captured revenue, a 12%+ reduction in A/R days, and a 43%+ reduction in coding-related denials. Founded by AI PhDs Nitesh Shroff and Preeti Bhargava, Arintra operates commercial functions out of Austin and core engineering in Bengaluru. With the new Series B funding, the company plans to scale its autonomous coding solution to more health systems and specialty groups.

Participated · Seed · Aug 2022

Freedom Biosciences develops next-generation viable and efficacious ketamine and psychedelic therapeutics, with a focus on improving durability and access to treatments for severe mental illness. Its lead program, FREE001, is a ketamine-specific treatment that in a Phase 2 investigational study produced approximately 14 days of antidepressant effects—two to three times longer than typical ketamine alone. The company says the new financing will be used to advance its lead ketamine program and to further multiple additional exploratory programs. Freedom was co-founded in April 2021 by Dr. John Krystal and Dina Burkitbayeva; Burkitbayeva serves as CEO and Krystal as Chief Scientific Advisor. The company emerged from stealth in 2022 and is backed by investors including MBX Capital, PsyMed Ventures and Village Global. Its leadership and advisory board include clinicians and researchers with extensive experience in ketamine and psychedelic research, supporting clinical development and regulatory strategy.

Participated · Seed · Jan 2015

Rally Bus operates a platform and mobile app that lets riders reserve seats on charter buses and use social media to reach a threshold for a trip to be confirmed. The company partners with charter bus operators nationwide to fulfill trips and positions its service as a "social mobility network" that enhances the event-day experience. Rally Bus cites more than 60,000 reservations from riders in over 1,000 North American cities and traces its origin to a 2010 effort that moved nearly 5,000 riders to a single event. The company raised a $1.25M seed round and plans to use proceeds to expand its team, ramp business development and marketing, and invest in technology. Rally Bus anticipates pursuing a Series A round during 2015.

Participated · Seed · Oct 2013

Panorama Education builds a K-12 education software platform that surveys students, parents and teachers to collect actionable data for schools. The platform integrates with district data systems to pull together a comprehensive view of student information and gives teachers tools to plan interventions. Panorama says it serves 13 million students in 23,000 schools, including more than 1,500 school districts and over 50 of the largest 100 districts and state agencies, with clients such as the New York City Department of Education and Clark County School District. Since March 2020 the company added 700 school districts, nearly doubling from 800 eighteen months earlier, and roughly 25 million people took a Panorama survey in the past year. Panorama reports about 250 employees and asserts district outcomes like improved graduation rates and fewer behavior referrals. The company plans to use new capital for continued product development, deeper district partnerships and hiring. Panorama Education is an edtech company founded in 2012 and based in Boston, MA, that provides a platform for school districts to measure and improve students' social-emotional learning, family engagement, and college readiness. Its core products include research-backed surveys to assess domains such as growth mindset, social awareness, and self-management, and Playbook, which offers strategies and resources guided by SEL data. A newer tool, Panorama Student Success, combines academic, attendance, behavior, and SEL data to give a holistic picture of each student and to identify students at risk of not graduating or needing coordinated services. Teachers, counselors, and principals use Playbook and the platform's resources, which include materials from partners like Second Step, Transforming Education, and Teaching Tolerance. The platform is used by 400 school systems, including the New York City Department of Education, Dallas Independent School District, San Francisco Unified School District, and Long Beach Unified School District. Panorama plans to use the funding to expand adoption of its tools to more districts. Panorama Education builds survey tools that collect feedback from students, parents, and teachers and combines those responses with existing school data to surface actionable insights. The platform lets districts choose focus areas (safety, trust in teachers, student potential, etc.) and adapts survey delivery to district needs (paper or email). Panorama works with thousands of schools across 220 districts in 40 states, reaching more than three million students, including 14 of the top 100 largest U.S. districts such as San Francisco Unified, Seattle Public Schools, and Dallas Independent. The company was founded in 2013 by Aaron Feuer and Xan Tanner. As districts adopt Panorama not only to diagnose issues but to report on interventions, the company aims to move from measurement toward prescribing solutions for educational problems. The business model emphasizes district sales and tailoring to varied communication infrastructures across wealthier and less-resourced districts. Panorama Education designs, administers and analyzes surveys (online, paper and phone) to give teachers and administrators insight into learning, school climate and social inclusion. The company combines anonymized survey data with other information to produce comparative analyses and recommendations. It currently serves roughly 4,000 schools covering over 1 million students, with clients including the Connecticut and Colorado state departments of education and the Los Angeles Unified School District (550,000 students). Panorama conducts large volumes of paper surveys (about half a million) and uses internal teams and systems to parse results and advise schools. The founders, Aaron Feuer and Xan Tanner, started the company in 2010 while undergraduates at Yale and the startup was incubated in Y Combinator earlier this year. Financial details are limited: pricing varies by engagement, Feuer declined to disclose current revenue, though in May the company had a run rate of about $500,000 when it had ~1,100 clients. Future plans include deeper U.S. market expansion, first international efforts via a Teach for All partnership across 17 countries starting with the U.K., and evolving beyond surveys toward broader problem-solving services for schools.

Participated · Series A · Nov 2012

New Haven Pharmaceuticals is a specialty pharmaceuticals company led by CEO Patrick Fourteau that develops prescription drug products using currently marketed drugs and generally recognized as safe (GRAS) active pharmaceutical ingredients. Its portfolio includes the FDA-approved DURLAZA™. The company is advancing products that incorporate proprietary Yale University technology utilizing zinc salts, including a zinc salts product designed to lower stomach acid in patients with gastro-esophageal reflux disease (GERD) and a combination product with DURLAZA. New Haven received a $6.3M venture loan from Horizon Technology Finance Corporation and, together with Horizon’s existing venture loan, now has $10M of debt capital. The company intends to use the proceeds for working capital to support its development activities. New Haven is based in North Haven, CT. New Haven Pharmaceuticals is a specialty pharmaceutical company based in Guilford, CT that develops prescription drug products built on proprietary controlled-release technologies and on active pharmaceutical ingredients generally recognized as safe. The company focuses on reformulations and therapeutics that utilize currently marketed drugs or APIs. It holds intellectual property licensed from Yale University to support its product programs. Leadership includes Patrick P. Fourteau as President & CEO and Harry H. Penner, Jr. as Executive Chairman. New Haven recently secured financing to support near-term operations and product development. The company intends to use the financing for working capital purposes. New Haven Pharmaceuticals develops controlled‑release specialty pharmaceuticals using technology licensed from Yale University and Flamel Technologies. Its lead candidate is a once‑daily, 24‑hour antiplatelet aspirin formulated with a micro‑pump technology (used in GSK’s Coreg CR) intended to extend intestinal transit and therapeutic effect. Follow‑on applications for the platform include arthritis, foreign body reaction, and liver injury in hepatitis C patients; the company is also developing a controlled‑release zinc salt formulation for breakthrough GERD. New Haven says the formulation aims to extend aspirin’s effect to 24 hours, reduce GI toxicity and improve compliance among the roughly 33 million Americans who take aspirin regularly. The company is anticipating an NDA filing for the first product next year, with planned U.S. and European launches in 2014. Financially, an SEC filing shows New Haven has raised $6.5M of a targeted $7.7M round so far, with 17 investors participating.